Diloxanide furoate

Paul G. Auwaerter, M.D., Kathryn Dzintars, Pharm.D., BCPS
Diloxanide furoate is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Drug not currently available for use in the U.S.
    • Also known in the literature as entamide furoate or entamide.
  • CDC conducted a study on the investigational use of the drug between 1977-1990.

NON-FDA APPROVED USES

  • Amebiasis, limited to the GI lumen, caused by Entamoeba histolytica.
  • As a combination therapy with other antiprotozoals, such as nitroimidazoles, for treating invasive or extraintestinal amebiasis. Diloxanide furoate is not a tissue amoebicide. Therefore, in extraintestinal infections of E. histolytica, another agent (specifically a "tissue amoebicide" like metronidazole) should be considered for use with diloxanide furoate.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Drug not currently available for use in the U.S.
    • Also known in the literature as entamide furoate or entamide.
  • CDC conducted a study on the investigational use of the drug between 1977-1990.

NON-FDA APPROVED USES

  • Amebiasis, limited to the GI lumen, caused by Entamoeba histolytica.
  • As a combination therapy with other antiprotozoals, such as nitroimidazoles, for treating invasive or extraintestinal amebiasis. Diloxanide furoate is not a tissue amoebicide. Therefore, in extraintestinal infections of E. histolytica, another agent (specifically a "tissue amoebicide" like metronidazole) should be considered for use with diloxanide furoate.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 18, 2022